Instil Bio
62 hedge funds and large institutions have $1.35B invested in Instil Bio in 2021 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 17 increasing their positions, 5 reducing their positions, and 21 closing their positions.
240% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 5
29% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 21
11% more funds holding
Funds holding: 56 → 62 (+6)
0.15% more ownership
Funds ownership: 2.58% → 2.74% (+0.15%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
17% less capital invested
Capital invested by funds: $1.62B → $1.35B (-$271M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$67M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$15.4M |
| 3 |
BlackRock
New York
|
+$14.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.8M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$30.6M |
| 2 |
Millennium Management
New York
|
-$8.72M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$6.68M |
| 4 |
HM
HealthCor Management
New York
|
-$5.02M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.76M |
TIL Hedge Fund Activity: Q2 2021 in Review
62 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Instil Bio (TIL) for Q2 2021, worth a combined $1.35B — down 17% from $1.62B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new TIL positions and 21 closed out — a net gain of 6 holders — while 17 added to existing stakes and 5 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $67M. The largest seller was Wellington Management Group, cutting an estimated $30.6M.
- 62 institutional investors held Instil Bio (TIL) as of Q2 2021, up from 56 in Q1 2021.
- Funds reported $1.35B of Instil Bio stock for Q2 2021, down 17% quarter-over-quarter.
- 27 funds opened new Instil Bio positions in Q2 2021 and 21 closed out, a net change of +6 holders.
- The largest Instil Bio buyer in Q2 2021 was Fidelity Investments, an estimated $67M added.
- The largest Instil Bio seller in Q2 2021 was Wellington Management Group, an estimated $30.6M sold.
Based on aggregated 13F filings for Q2 2021.